ESG News For Bristol-Myers Squibb Company

The Robert A. Winn Excellence in Clinical Trials Award Program (Winn Awards) recently announced 79 new physician-researchers from across the United States have been selected to join the fifth annual cohort of the Winn Career Development Award (Winn CDA) program.

Recently, the Innovative Cancer Medicines (ICM) initiative announced the enrollment of the first Nigerian patient in a pioneering demonstration project to provide an immunotherapy drug used to treat cancer.

PATH has launched a groundbreaking initiative to address the rising burden of hemoglobinopathies—particularly Thalassemia—in India, with the support of a grant from the Bristol Myers Squibb Foundation (BMS Foundation). The program aims to strengthen local health systems.

HopeHealth announced that it is participating in a pivotal phase 3 clinical research study, sponsored by global pharmaceutical company Bristol Myers Squibb (BMS), to evaluate an investigational treatment in patients with systemic lupus erythematosus (SLE).

The Bristol Myers Squibb Foundation (BMS Foundation), an independent charitable organization whose mission is to improve global health, recently announced a $1 million donation to the Patient Advocate Foundation.

At Bristol Myers Squibb (BMS), we believe that how we communicate can be just as important as what we’re communicating — especially when it comes to people’s health.

Recently, Bristol Myers Squibb (NYSE: BMY) and the National Community Pharmacists Association (NCPA) announced a new collaboration aimed at improving heart health in rural communities in the United States.

The Robert A. Winn Clinical Investigator Pathway Program (Winn CIPP), a national program out of VCU Massey Comprehensive Cancer Center, has officially launched its fourth annual cohort, taking place during the summer of 2025.

A groundbreaking lung cancer screening project co-led by the University of Kentucky Markey Cancer Center and the University of Colorado (CU) Cancer Center is set to expand its reach, thanks to a $6.8 million grant from the Bristol Myers Squibb Foundation.

We are in an era of unprecedented medical innovation. Scientists are making remarkable progress to diagnose and treat diseases, bringing new hope to patients across the world. Unfortunately, these breakthroughs fail to reach everyone due to barriers to care.

Bristol Myers Squibb announced that it has been named in the prestigious Dow Jones Sustainability Index (DJSI) for the second consecutive year. This recognition further validates the company’s impactful progress towards and prioritization of its ESG initiatives and aspirations.

Early detection through screening is key to improving lung cancer survivorship – when lung cancer is discovered early enough to be surgically removed before spreading, a patient's chance of surviving five years jumps from 4% to 55%.

Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research

“Humankind 100” ranking celebrates companies’ positive human impactAlphabet earns the top spot for the third year in a row

At BMS, our vision to transform patients’ lives through science extends to all patients. That is why we have a long-standing commitment to promote health equity and help people in underserved communities access the care and medicines they need.

At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development and delivery of innovative medicines that help patients prevail over serious diseases.

BMS today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), as part of a mid-year update on its environmental initiatives, highlighting progress in reducing emissions across its operations and supply chain.

BMS has earned a top score of 100 on the 2024 Disability Equality Index®, naming BMS a Best Place to Work for Disability Inclusion in the U.S., U.K. and Brazil. BMS has earned this score for the sixth consecutive year in the U.S. and for the first time in the U.K. and Brazil.

ristol Myers Squibb (NYSE: BMY) has been named to the prestigious 2023 Dow Jones Sustainability Index (DJSI) North America, validating the company’s meaningful progress, evolved strategy and aspirational goals toward its environmental, social and governance efforts.

Globally, communities are struggling to support growing healthcare needs. This is especially true in regions with limited financial resources, collectively known as low- and middle-income countries (LMICs). Although LMIC populations have grown nearly four times faster.

The Company enters strategic collaboration with the Access to Oncology Medicines (ATOM) Coalition to expand access to immuno-oncology therapy Opdivo™ in select countries

BMS announced ASPIRE (Accessibility, Sustainability, Patient-centric, Impact, Responsibility and Equity), a 10-year strategy to advance access to our innovative treatments and help patients in low- and middle-income countries.

Since 1887, BMS has enabled positive change for patients around the world, and I am honored to continue this legacy as Board Chair and CEO. Our obligation to advance this legacy is profound.

Bristol Myers Squibb (NYSE: BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company’s meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts.

Company builds on its strengths to advance patient access, product innovation, culture and inclusion and diversity

Bristol Myers Squibb published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company’s meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts.

Bristol Myers Squibb (NYSE: BMY) unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom.

Bristol Myers Squibb Company ranks in top 10 of Pharmaceutical and Biotech Sector on the issues Americans care about most

Bristol Myers Squibb announced it has been recognized as One of America's Most JUST Companies. The ranking, presented by JUST Capital and CNBC, recognized BMS for its commitment to key social responsibilities, including employees, customers, communities, and environmental impact.

65 physicians comprise Cohort III, bringing the total to 179 participants in the program’s third year

Over 126 employees from the U.S., Canada and Puerto Rico will relay nearly 3,000 miles from the coast of Oregon to the New Jersey Shore

- Achieves $1 billion investment goal with diverse-owned suppliers- Expanding diverse-owned supplier spend globally to increase impact

- Commitments demonstrate leadership in advancing health equity and workforce representation to better serve patients and communities- $10 million in 2023 grant funding to 17 U.S. organizations focused on addressing social determinants of health- Expanding aspirational workforce representation goals for those in senior leadership roles

64 physicians comprise Cohort II, bringing the total to 116 participants in the program’s second year

Inaugural “Humankind 100” ranking celebrates companies with purposeAlphabet scores highest in this year’s ranking

Recap of CSR stories on Business Wire

Grants going to 24 U.S. non-profit organizations to train and support community health workers and patient navigators as part of $150 million D&I and Health Equity Commitments by 2025

52 physicians from across the U.S. selected for the inaugural cohort of the five-year, $100 million initiativeInitiative is part of the BMS Foundation commitment to health equity and diversity and inclusion made last yearApplications are also now open for second cohort to begin in October 2022

Recap of CSR stories on Business Wire

Riders aspire to raise more than $1 million for the V Foundation for Cancer Research and make a profound difference for patients and families touched by cancer

The Supply Surge rallies local businesses and community partners to support students in need

The Melanoma Research Alliance, the largest non-profit funder of melanoma research, is proud to announce $8.1 million in funding for 34 new research awards. The awards, issued near the start of Melanoma Awareness Month, provide critical funding to address urgent unmet needs in melanoma.“COVID-19 has impacted so much, including research and clinical trials. This investment in melanoma research is needed now more than ever,” said MRA Board Chair and Co-Founder Debra Black. “We’re proud to support

The RepTrak Company Releases 2021 Global RepTrak® 100: Harder than Ever Before to Join Ranking, ESG is Key

Fellowship program honors Dr. Just, a pioneering biologist and one of the most prominent African American scientists of the twentieth century

Five–year commitment builds on long-standing investment in health equity

Annual Event Takes Digital Approach to Victory Over Cancer®

Grants include additional geographies, areas of focus and disease targets

BMS Receives 2019 ENERGY STAR® Partner of the Year – Sustained Excellence Award

Recap of CSR stories on Business Wire

More than 100 company employees will ride across the country with the goal of raising $1 million for cancer research